Bugide S, Edwards YJK, Gupta R, Green MR, et al. CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer. Proc Natl Acad Sci U S A 2023;120:e2218118120.
PMID: 36652476